Literature DB >> 7581961

Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response.

L Lazar1, R Kauli, C Bruchis, J Nordenberg, A Galatzer, A Pertzelan.   

Abstract

Exaggerated adrenal response (ExAR), i.e. hypersecretion of both 17-hydroxypregnenolone (170HPreg) and 17-hydroxyprogesterone(17OHP) in response to adrenocorticotropic hormone (ACTH) stimulation, is frequently found in women with polycystic ovary (PCO) syndrome who had precocious adrenarche. In an earlier study we found an abnormal adrenal response in girls with idiopathic true central precocious puberty (CPP) at early stages of puberty. On follow-up it was noted that a significant number of girls with CPP develop PCO-like syndrome at a relatively young age. The aim of the present study was to determine if there is an association between ExAR and early PCO in girls with a history of CPP. Included were 49 girls with a history of CPP, 34 of whom were treated with gonadotropin-releasing hormone (GnRH) analog. All 49 were evaluated at full maturity, at ages 12.5-14 years, 0.5-4 years after menarche or resumption of menses. Of the 49 girls, 20 had at least 3/4 clinical signs of PCO (irregular menses, hirsutism, acne and obesity) and were defined as PCO-like+, whereas 29 did not fulfil the criteria and were considered PCO-like-. Girls with a definite enzyme deficiency were excluded from the study. All participants underwent a combined iv ACTH-GnRH test at early follicular phase. The PCO-like+ girls all revealed ExAR, i.e. an elevated stimulated 17OHPreg of 63.4 +/- 9.6 nmol/l (normal 28.6 +/- 9.2 nmol/l) and a normal stimulated 17OHPreg/17OHP ratio of 7.1 +/- 1.8 (normal 6.2 +/- 2.7), whereas all the PCO-like- had a normal adrenal response (30.0 +/- 8.7 and 5.3 +/- 2.0 nmol/l, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7581961     DOI: 10.1530/eje.0.1330403

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

Review 1.  Follow-up of children and young adults after GnRH-agonist therapy or central precocious puberty.

Authors:  P P Feuillan; J V Jones; K Barnes; K O Klein; G B Cutler
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

Review 2.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 3.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

4.  Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome.

Authors:  Tugba Unsal; Ece Konac; Ediz Yesilkaya; Akin Yilmaz; Aysun Bideci; Hacer Ilke Onen; Peyami Cinaz; Adnan Menevse
Journal:  J Assist Reprod Genet       Date:  2009-04-22       Impact factor: 3.412

Review 5.  Normal and Premature Adrenarche.

Authors:  Robert L Rosenfield
Journal:  Endocr Rev       Date:  2021-11-16       Impact factor: 19.871

Review 6.  Long-term effects of gonadotropin-releasing hormone analogs in girls with central precocious puberty.

Authors:  Eun Young Kim
Journal:  Korean J Pediatr       Date:  2015-01-31

7.  Pregnancy-related outcomes for women with polycystic ovary syndrome.

Authors:  Rose McDonnell; Roger J Hart
Journal:  Womens Health (Lond)       Date:  2017-09-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.